Preclinical trials have demonstrated the benefits of using S1PR1 modulators in IBD therapy to modulate intestinal leukocyte migration by reducing inflammatory immune cells into the mucosa, reducing inflammatory cytokines, and expanding regulatory T-cells [152]. The gene discussed is S1PR1; the disease is inflammatory bowel disease.